Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT)

Acumen Pharmaceuticals (NASDAQ:ABOS) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares Acumen Pharmaceuticals and Bolt Biotherapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$102.33 million	($2.22)	-0.96
Bolt Biotherapeutics	$7.69 million	1.36	-$63.12 million	($22.38)	-0.24

Bolt Biotherapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Acumen Pharmaceuticals and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-97.41%	-70.41%
Bolt Biotherapeutics	N/A	-94.22%	-50.56%

Insider and Institutional Ownership

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Acumen Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Acumen Pharmaceuticals and Bolt Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1	0	4	0	2.60
Bolt Biotherapeutics	1	2	2	0	2.20

Acumen Pharmaceuticals currently has a consensus target price of $6.75, indicating a potential upside of 215.42%. Bolt Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 525.00%. Given Bolt Biotherapeutics’ higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Acumen Pharmaceuticals.

Summary

Bolt Biotherapeutics beats Acumen Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.